Previous Close | 1,254.65 |
Open | 1,229.55 |
Bid | 1,256.90 x 0 |
Ask | 1,257.45 x 0 |
Day's Range | 1,227.40 - 1,263.50 |
52 Week Range | 665.65 - 1,292.15 |
Volume | |
Avg. Volume | 50,501 |
Market Cap | 735.881B |
Beta (5Y Monthly) | 0.51 |
PE Ratio (TTM) | 23.22 |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | 4.50 (0.36%) |
Ex-Dividend Date | Feb 20, 2024 |
1y Target Est | N/A |
Aurobindo Pharma (NS:ARBN) has outperformed expectations in the fourth quarter of FY24, with both sales and EBITDA showing significant year-over-year growth. Sales increased by 17%, while EBITDA surged by an impressive 68%, surpassing both Goldman Sachs (NYSE:GS)' projections and those of the broader market. The EBITDA margin also exceeded forecasts, reaching 22.3%, which is 101 basis points higher than Goldman Sachs' estimate.